Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
1.
Vaccine ; 34(50): 6223-6228, 2016 12 07.
Artigo em Inglês | MEDLINE | ID: mdl-27847175

RESUMO

BACKGROUND: Pertussis disease is a growing concern for developing countries. In Argentina, rates of illness and death peaked in 2011. More than 50% of fatalities due to pertussis occurred in infants younger than two months of age, too young for vaccination. In 2012, the government offered immunization with a vaccine containing Tdap to all pregnant women after 20weeks of gestation with the intent of reducing morbidity and mortality in young infants. METHODS: Maternal acellular pertussis vaccine impact on reducing infant disease burden was estimated based on data from the Argentinean Health Surveillance System. We divided Argentinean states in two groups experiencing high (>50) and low (⩽50) Tdap vaccine coverage and compared these two groups using a Bayesian structural time-series model. Low coverage regions were used as a control group, and the time series were compared before and after the implementation of the Tdap program. FINDINGS: We observed a relative reduction of 51% (95% CI [-67%, -35%]; p=0.001) in pertussis cases in high coverage states in comparison with the low coverage areas. Analysis of infants between two and six months showed a 44% (95% CI [-66%, -24%]; p=0.001) reduction in illness. Number of deaths was highest in 2011 with 76 fatalities, for an incidence rate of 2.9 per 100,000. Comparing with 2011, rates decreased by 87% to 10 subjects, or 0.9 per 100,000 in 2013. INTERPRETATION: We show an age-dependent protective effect of maternal Tdap immunization in a developing country for infants younger than six months.


Assuntos
Vacinas contra Difteria, Tétano e Coqueluche Acelular/administração & dosagem , Transmissão de Doença Infecciosa/prevenção & controle , Programas de Imunização , Gestantes , Vacinação/estatística & dados numéricos , Coqueluche/epidemiologia , Coqueluche/prevenção & controle , Argentina/epidemiologia , Criança , Pré-Escolar , Países em Desenvolvimento , Feminino , Humanos , Incidência , Lactente , Recém-Nascido , Masculino
2.
Arch Argent Pediatr ; 113(1): e81-2, 2015 01.
Artigo em Espanhol | MEDLINE | ID: mdl-25785298
3.
Arch. argent. pediatr ; 113(1): e81, ene. 2015.
Artigo em Espanhol | LILACS-Express | LILACS, BINACIS | ID: biblio-1159657
4.
Arch Argent Pediatr ; 113(1): e81-2, 2015 Jan.
Artigo em Espanhol | BINACIS | ID: bin-133765
5.
Arch. argent. pediatr ; 112(5): 413-420, oct. 2014. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-734270

RESUMO

Introducción. Coqueluche constituye un problema de salud pública. Objetivos: Describir la morbimortalidad y coberturas de vacunación entre 2002 y 2011, el perfil de los casos de 2011 y las estrategias de control implementadas por el Ministerio de Salud (MSN). Métodos. Estudio descriptivo de vigilancia epidemiológica. Los datos de morbilidad se tomaron del Sistema Nacional de Vigilancia, y los de mortalidad, de la Dirección de Estadística e Información en Salud del MSN y de los informes oficiales de las jurisdicciones. Se utilizó la cobertura administrativa de vacunación a partir de datos provistos por las jurisdicciones al MSN. Se analizó con Epiinfo 7.1.2. Resultados. Entre 2002 y 2011, la notificación de casos de coqueluche y de fallecimientos se incrementó y alcanzó los mayores valores en 2011: tasa de 16 x 100 000 habitantes y 76 fallecidos. Las muertes ocurrieron mayoritariamente en <1 año y las coberturas nacionales de vacunación para 3ra dosis e ingreso escolar fueron >90% y para el primer refuerzo, 80-90%. En 2011, se notificaron 2821 casos confirmados (incidencia 7 x 100 000 hab.): 84% <1 año; 76 fallecidos: 97% <1 año (60,5% <2 meses). Entre las estrategias implementadas, se consolidaron 906 nodos clínicos y 405 de laboratorio; se implementaron la reacción en cadena de la polimerasa como método diagnóstico y la clasificación diferencial de los casos, y se incorporaron dosis adicionales de vacunación. Conclusiones . Entre 2002 y 2011, aumentaron los casos de coqueluche; la mayor morbimortalidad fue en <1 año, con coberturas de vacunación de 80 y 90%. . El mayor número de fallecidos por coqueluche fue en el año 2011. . El MSN fortaleció la vigilancia epidemiológica y orientó las medidas de control.


Introduction. Pertussis is a challenge for public health. Objectives: To describe pertussis-related morbidity and mortality and immunization coverage for the 2002-2011 period, profile of cases for 2011, and control strategies implemented by the Ministry of Health (MoH) of Argentina. Methods. Descriptive, epidemiological surveillance study. Morbidity data were obtained from the National Health Surveillance System, while mortality data were obtained from the MoH's Health Statistics and Information Department and official jurisdictional reports. Administrative immunization coverage was used based on the data provided by the MoH's jurisdictions. The Epi Info software, version 7.1.2, was used for analysis. Results. The number of reported cases of pertussis increased between 2002 and 2011, reaching its peak in 2011: an incidence of 16 x 100 000 inhabitants, and 76 deaths. Most deaths occurred in infants younger than 1 year old. Immunization coverage achieved at a national level with the third dose and the dose administered at the time of starting primary education was >90%, while the coverage achieved with the first booster dose was 80%-90%. In 2011, 2821 confirmed cases were reported (incidence of 7 x 100 000 inhabitants): 84% in infants <1 year old; 76 deaths: 97% in infants <1 year old (60.5% in infants <2 months old). Among the strategies that were deployed, a total of 906 clinical nodes and 405 laboratory nodes were consolidated; the use of the polymerase chain reaction as a diagnostic method and the differential classification of cases were implemented, and additional vaccine doses were administered. Conclusions . The number of pertussis cases increased between2002 and 2011; the highest morbidity and mortality occurred ininfants younger than 1 year old; immunization coverage reached 80%-90%. . The highest number of pertussis-related deaths was recorded in 2011. . The MoH strengthened the epidemiological surveillance and set guidelines for control measures.


Assuntos
Adolescente , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Coqueluche/epidemiologia , Coqueluche/prevenção & controle , Argentina/epidemiologia , Monitoramento Epidemiológico , Incidência , Vacina contra Coqueluche
6.
Arch. argent. pediatr ; 112(5): 413-420, oct. 2014. ilus, tab
Artigo em Espanhol | BINACIS | ID: bin-131536

RESUMO

Introducción. Coqueluche constituye un problema de salud pública. Objetivos: Describir la morbimortalidad y coberturas de vacunación entre 2002 y 2011, el perfil de los casos de 2011 y las estrategias de control implementadas por el Ministerio de Salud (MSN). Métodos. Estudio descriptivo de vigilancia epidemiológica. Los datos de morbilidad se tomaron del Sistema Nacional de Vigilancia, y los de mortalidad, de la Dirección de Estadística e Información en Salud del MSN y de los informes oficiales de las jurisdicciones. Se utilizó la cobertura administrativa de vacunación a partir de datos provistos por las jurisdicciones al MSN. Se analizó con Epiinfo 7.1.2. Resultados. Entre 2002 y 2011, la notificación de casos de coqueluche y de fallecimientos se incrementó y alcanzó los mayores valores en 2011: tasa de 16 x 100 000 habitantes y 76 fallecidos. Las muertes ocurrieron mayoritariamente en <1 año y las coberturas nacionales de vacunación para 3ra dosis e ingreso escolar fueron >90% y para el primer refuerzo, 80-90%. En 2011, se notificaron 2821 casos confirmados (incidencia 7 x 100 000 hab.): 84% <1 año; 76 fallecidos: 97% <1 año (60,5% <2 meses). Entre las estrategias implementadas, se consolidaron 906 nodos clínicos y 405 de laboratorio; se implementaron la reacción en cadena de la polimerasa como método diagnóstico y la clasificación diferencial de los casos, y se incorporaron dosis adicionales de vacunación. Conclusiones . Entre 2002 y 2011, aumentaron los casos de coqueluche; la mayor morbimortalidad fue en <1 año, con coberturas de vacunación de 80 y 90%. . El mayor número de fallecidos por coqueluche fue en el año 2011. . El MSN fortaleció la vigilancia epidemiológica y orientó las medidas de control.(AU)


Introduction. Pertussis is a challenge for public health. Objectives: To describe pertussis-related morbidity and mortality and immunization coverage for the 2002-2011 period, profile of cases for 2011, and control strategies implemented by the Ministry of Health (MoH) of Argentina. Methods. Descriptive, epidemiological surveillance study. Morbidity data were obtained from the National Health Surveillance System, while mortality data were obtained from the MoHs Health Statistics and Information Department and official jurisdictional reports. Administrative immunization coverage was used based on the data provided by the MoHs jurisdictions. The Epi Info software, version 7.1.2, was used for analysis. Results. The number of reported cases of pertussis increased between 2002 and 2011, reaching its peak in 2011: an incidence of 16 x 100 000 inhabitants, and 76 deaths. Most deaths occurred in infants younger than 1 year old. Immunization coverage achieved at a national level with the third dose and the dose administered at the time of starting primary education was >90%, while the coverage achieved with the first booster dose was 80%-90%. In 2011, 2821 confirmed cases were reported (incidence of 7 x 100 000 inhabitants): 84% in infants <1 year old; 76 deaths: 97% in infants <1 year old (60.5% in infants <2 months old). Among the strategies that were deployed, a total of 906 clinical nodes and 405 laboratory nodes were consolidated; the use of the polymerase chain reaction as a diagnostic method and the differential classification of cases were implemented, and additional vaccine doses were administered. Conclusions . The number of pertussis cases increased between2002 and 2011; the highest morbidity and mortality occurred ininfants younger than 1 year old; immunization coverage reached 80%-90%. . The highest number of pertussis-related deaths was recorded in 2011. . The MoH strengthened the epidemiological surveillance and set guidelines for control measures.(AU)

7.
Arch Argent Pediatr ; 112(5): 413-20, 2014 10.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-25192521

RESUMO

INTRODUCTION: Pertussis is a challenge for public health. OBJECTIVES: To describe pertussis-related morbidity and mortality and immunization coverage for the 2002-2011 period, profile of cases for 2011, and control strategies implemented by the Ministry of Health (MoH) of Argentina. METHODS: Descriptive, epidemiological surveillance study. Morbidity data were obtained from the National Health Surveillance System, while mortality data were obtained from the MoH's Health Statistics and Information Department and official jurisdictional reports. Administrative immunization coverage was used based on the data provided by the MoH's jurisdictions. The Epi Info software, version 7.1.2, was used for analysis. RESULTS: The number of reported cases of pertussis increased between 2002 and 2011, reaching its peak in 2011: an incidence of 16 x 100 000 inhabitants, and 76 deaths. Most deaths occurred in infants younger than 1 year old. Immunization coverage achieved at a national level with the third dose and the dose administered at the time of starting primary education was >90%, while the coverage achieved with the first booster dose was 80%-90%. In 2011, 2821 confirmed cases were reported (incidence of 7 x 100 000 inhabitants): 84% in infants <1 year old; 76 deaths: 97% in infants <1 year old (60.5% in infants <2 months old). Among the strategies that were deployed, a total of 906 clinical nodes and 405 laboratory nodes were consolidated; the use of the polymerase chain reaction as a diagnostic method and the differential classification of cases were implemented, and additional vaccine doses were administered. CONCLUSIONS: The number of pertussis cases increased between 2002 and 2011; the highest morbidity and mortality occurred in infants younger than 1 year old; immunization coverage reached 80%-90%. . The highest number of pertussis-related deaths was recorded in 2011. The MoH strengthened the epidemiological surveillance and set guidelines for control measures.


Assuntos
Coqueluche/epidemiologia , Coqueluche/prevenção & controle , Adolescente , Argentina/epidemiologia , Criança , Pré-Escolar , Monitoramento Epidemiológico , Feminino , Humanos , Incidência , Lactente , Recém-Nascido , Masculino , Vacina contra Coqueluche
8.
Arch Argent Pediatr ; 112(5): 413-20, 2014 Oct.
Artigo em Espanhol | BINACIS | ID: bin-133241

RESUMO

INTRODUCTION: Pertussis is a challenge for public health. OBJECTIVES: To describe pertussis-related morbidity and mortality and immunization coverage for the 2002-2011 period, profile of cases for 2011, and control strategies implemented by the Ministry of Health (MoH) of Argentina. METHODS: Descriptive, epidemiological surveillance study. Morbidity data were obtained from the National Health Surveillance System, while mortality data were obtained from the MoHs Health Statistics and Information Department and official jurisdictional reports. Administrative immunization coverage was used based on the data provided by the MoHs jurisdictions. The Epi Info software, version 7.1.2, was used for analysis. RESULTS: The number of reported cases of pertussis increased between 2002 and 2011, reaching its peak in 2011: an incidence of 16 x 100 000 inhabitants, and 76 deaths. Most deaths occurred in infants younger than 1 year old. Immunization coverage achieved at a national level with the third dose and the dose administered at the time of starting primary education was >90


, while the coverage achieved with the first booster dose was 80


-90


. In 2011, 2821 confirmed cases were reported (incidence of 7 x 100 000 inhabitants): 84


in infants <1 year old; 76 deaths: 97


in infants <1 year old (60.5


in infants <2 months old). Among the strategies that were deployed, a total of 906 clinical nodes and 405 laboratory nodes were consolidated; the use of the polymerase chain reaction as a diagnostic method and the differential classification of cases were implemented, and additional vaccine doses were administered. CONCLUSIONS: The number of pertussis cases increased between 2002 and 2011; the highest morbidity and mortality occurred in infants younger than 1 year old; immunization coverage reached 80


-90


. . The highest number of pertussis-related deaths was recorded in 2011. The MoH strengthened the epidemiological surveillance and set guidelines for control measures.

15.
Arch Argent Pediatr ; 108(1): 71-4, 2010 Feb.
Artigo em Espanhol | MEDLINE | ID: mdl-20204243

RESUMO

Following the presentation of a confirmed case of paralytic polio Sabin-derived virus (VSD) in a child of 15 months we analyzed the coverage of poliomyelitis vaccination in children living in the City of Buenos Aires, in the 2006/2008 triennium. There was an improvement over the period analyzed, but values above 95% were reached only for the first dose. The proportion of inactivated vaccine (IPV) increased at the expense of live oral vaccine (OPV); in 2008, the first dose IPV coverage was 37.64% and 19.48% for the school entrance. The lack of intestinal immunity that occurs in children immunized with IPV, plus a poor coverage with OPV, allows the circulation of wild virus or VSD favoring the occurrence of paralytic poliomyelitis in unvaccinated or immunocompromised children.


Assuntos
Vacinas contra Poliovirus , Vacinação/estatística & dados numéricos , Argentina , Criança , Humanos , Saúde da População Urbana
16.
Arch. argent. pediatr ; 108(1): 71-74, feb. 2010. tab
Artigo em Espanhol | LILACS | ID: lil-542475

RESUMO

A raíz de la presentación de un caso confirmado de poliomielitis paralítica por virus Sabin derivado (VSD) en niños de 15 meses se analizó la cobertura de vacunación antipoliomielítica en niños residentes en la Ciudad de Buenos Aires, durante el trienio 2006/2008. Se observó una mejora a lo largo del período analizado, pero sólo hubo valores superiores al 95 por ciento para la primera dosis. Aumentó la proporción de vacuna inactivada (IPV) en desmedro de la vacuna oral viva (OPV); en 2008, la cobertura con IPV primera dosis fue del 37,64 por ciento y del 19,48 por ciento para el ingreso escolar. La falta de inmunidad intestinal que se presenta en los niños vacunados con IPV, asociada a coberturas insatisfactorias condiciona un terreno propicio para la circulación de virus salvaje o VSD, lo cual favorece la aparición de casos de poliomielitis paralítica en niños no vacunados o inmunodeficientes.


Assuntos
Humanos , Masculino , Lactente , Pré-Escolar , Criança , Feminino , Cobertura Vacinal , Poliomielite , Vacina Antipólio Oral/administração & dosagem , Vacina Antipólio Oral/efeitos adversos , Vacina Antipólio de Vírus Inativado/administração & dosagem , Vacina Antipólio de Vírus Inativado/efeitos adversos
17.
Arch. argent. pediatr ; 108(1): 71-74, feb. 2010. tab
Artigo em Espanhol | BINACIS | ID: bin-125802

RESUMO

A raíz de la presentación de un caso confirmado de poliomielitis paralítica por virus Sabin derivado (VSD) en niños de 15 meses se analizó la cobertura de vacunación antipoliomielítica en niños residentes en la Ciudad de Buenos Aires, durante el trienio 2006/2008. Se observó una mejora a lo largo del período analizado, pero sólo hubo valores superiores al 95 por ciento para la primera dosis. Aumentó la proporción de vacuna inactivada (IPV) en desmedro de la vacuna oral viva (OPV); en 2008, la cobertura con IPV primera dosis fue del 37,64 por ciento y del 19,48 por ciento para el ingreso escolar. La falta de inmunidad intestinal que se presenta en los niños vacunados con IPV, asociada a coberturas insatisfactorias condiciona un terreno propicio para la circulación de virus salvaje o VSD, lo cual favorece la aparición de casos de poliomielitis paralítica en niños no vacunados o inmunodeficientes.(AU)


Assuntos
Humanos , Masculino , Lactente , Pré-Escolar , Criança , Feminino , Cobertura Vacinal , Vacina Antipólio de Vírus Inativado/efeitos adversos , Vacina Antipólio Oral/efeitos adversos , Vacina Antipólio de Vírus Inativado/administração & dosagem , Vacina Antipólio Oral/administração & dosagem , Poliomielite
18.
Rev. Soc. Boliv. Pediatr ; 48(2): 114-122, 2009.
Artigo em Espanhol | LILACS | ID: lil-652498

RESUMO

En el contexto del Protocolo para un evaluación del Impacto de los Programas de Vacunación contra Haemophilus influenzae tipo b, en cuatro paises latinoamericanos". Estimar el impacto de la vacunación anti-Hib mediante la evaluación de la tasa de portación nasofaringéna. Identificar factores asociados a la portación de Haemophilus influenzae.


Assuntos
Humanos , Vacinas contra Influenza , Vacinas
20.
Arch. argent. pediatr ; 105(6): 498-505, dic.2007. graf, tab
Artigo em Espanhol | LILACS | ID: lil-478469

RESUMO

Introducción. En el contexto del “Protocolo parauna evaluación del Impacto de los Programas de Vacunación contra Haemophilus influenzae tipo b, encuatro países latinoamericanos” auspiciado por laOPS, se efectuó un estudio en Argentina luego de 8años de introducción de la vacuna anti-Hib.Objetivos. Estimar el impacto de la vacunaciónanti-Hib mediante la evaluación de la tasa de portación nasofaríngea. Identificar factores asociados ala portación de Haemophilus influenzae.Métodos. Estudio de corte transversal, junio 2005-abril 2006, en el Hospital de Niños “Dr. Ricardo Gutiérrez”y el Hospital de NIños “Dr. Pedro de Elizalde”.Las muestras de hisopado nasofarígeo se procesaronen el INEI-ANLIS “Dr. Carlos Malbrán”, se realizó cultivo en agar chocolate con bacitracina, se identificóH. influenzae mediante Gram, oxidasa, catalasa, requerimiento de factores y prueba de la porfirina. Laserotipificación capsular se realizó por aglutinaciónen lámina con antisueros específicos y su confirmación por reacción en cadena de la polimerasa.Población. 900 niños de 1 año y 700 de 5 años, con3 y 4 dosis de vacuna, respectivamente. Resultados. Hi se detectó en el 40% (641/1.600) delas muestras; entre los Hi, 4,8% (31/641) fueroncapsulados. Los Hi capsulados fueron: 3 serotipo a,1b, 3c, 5d, 7e y 12f. Sólo un niño de 1 año fueportador de Hib (tasa= 0,06%). Los factores asociadosa la portación de Hi fueron: la edad, convivircon algún hermano menor de 18 años y concurrir ajardín maternal.Conclusiones. Se halló una tasa de portación nasofaríngeade Hib muy baja, de 0,06%; por ello, no sepudieron analizar asociaciones. La edad, los contactos familiares y los extradomiciliarios se asociaroncon la portación de Haemophilus influenzae.


Introduction. As a part of the PAHO supported protocol “Evaluation of the impact of Haemophilus influenzae b vaccination programs in four Latinamerican countrys”, a study took place in Argentine 8 years after introduction of Hib vaccine Objective. To evaluate the impact of Hib vaccination measuring Nasopharyngeal Colonization (NC)rate and to identify factors associated to Haemophilus influenzae (HI) carrier status. Methods. Cross-sectional study –from June 27th 2005 to April 12th 2006– in two pediatric hospitals, HNRG and PE. Nasopharyngeal swab specimens were processed in the INEI-ANLIS “Dr. C. Malbrán”; samples were cultured in chocolate agar medium containing bacitracin. Hi was identified with technics of Gram, oxidase, catalase, growth factors (V-X-XV) and test of porphyrin. Capsular serotypification was made by agglutination in lamina with specific antisera and the confirmation by polymerase chain reaction. Population. 900 children of 1 year of age, vaccinated with 3 doses and 700 children of 5 years, with 4 vaccine doses. Results. Hi was detected in 40% (641/1.600) of samples, among Hi, 4,8% (31/641) were encapsulated (3 serotypes a, 1 b, 3 c, 5 d, 7 e, and 12 f). Only one child of 1 year was NC carrier of Hi type b (0.06%). Conclusions. We found a very low NC Hib (0.06%) rate, for this reason associations could not be analyzed. The age, household and day care center contacts were associated with NC by Haemophilus influenzae.


Assuntos
Criança , Haemophilus influenzae tipo b , Consentimento Livre e Esclarecido , Vacinas , Estudos Transversais , Coleta de Dados , Estudos Prospectivos , Interpretação Estatística de Dados
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...